PCN169 COST-EFFECTIVENESS ANALYSIS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB FOR THE FIRST-LINE TREATMENT OF ADVANCED/METASTATIC RENAL CELL CARCINOMA IN GREECE
Abstract
Authors
F. Diamantogiannis P. Viktoratos J. May B. Malcolm Van de Wetering G T. Ignacio